Company intelligence / Profile preview

BW Therapeutics

Tampa, Florida, United Statesbwtherapeutics.com ↗
Ownership
Private
Employees
~1
Development stage
Other
01

Overview

BW Therapeutics was a private U.S. biotechnology company based in Tampa, Florida, focused on oncology drug development. The company was founded in 2019 and centered its pipeline on TYN-21, described as a proprietary 505(b)(2) formulation of paclitaxel intended to provide equivalency to Abraxane. Publicly available information suggests BW Therapeutics pursued a relatively narrow, single-asset strategy and was seeking Series A financing and strategic partnering in early 2020. Company databases now list the business as closed, with no evidence of an approved product or active late-stage clinical pipeline.

Therapeutic areas
Oncology
Modalities
Small molecule
Industry
Biotech

Beyond the preview

Go deeper on BW Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BW Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call